PLX
Protalix Biotherapeutics
$2.59
+$0.06 (+2.37%)Oct 28, 2026
Key metrics
The numbers that frame PLX today
- Market cap
- $208.68M
- P/E (TTM)
- 11.3
- EV / FCF
- 24.7
- Gross margin
- 69.2%
- EV / Sales
- 2.4
- ROIC
- 48.1%
- Div yield
- 0%
- Debt / equity
- 0.1
- 52wk Low
- $1.65
- 52wk High
- $3.19
Growth
Revenue and earnings trend for PLX
RevenueNet income
See the full growth breakdown
Revenue and earnings trends, margins and the multi-year trajectory - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inCash flow & returns
Free cash flow and financial health
Free cash flowNet debt
See the full cash-flow picture
Free cash flow detail, returns on capital and the balance-sheet trend - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inInsider trading
Recent insider buying and selling activity
PurchasesSales
Unlock every insider trade
See who is buying and selling, how much, and when - updated as new filings land.
Create a free accountFree foreverNo card required
Already a member? Log inFrequently asked questions
Plain-English answers about PLX
Is Protalix Biotherapeutics a good buy?
Yes. Protalix Biotherapeutics has strong quality and excellent momentum. Both signals support the setup. Growth looks strong, which supports the long-term business case. We think Protalix Biotherapeutics is selling at a low price.
What is the market capitalization of PLX?
Protalix Biotherapeutics's market capitalization is $208.68M.
What is the P/E (TTM) ratio for PLX stock?
Protalix Biotherapeutics's P/E (TTM) ratio is 11.3, based on trailing earnings.
What is the 52-week high for PLX stock?
The 52-week high for Protalix Biotherapeutics is $3.19. The current close of $2.59 is 18.8% below that high.
What is the 52-week low for PLX stock?
The 52-week low for Protalix Biotherapeutics is $1.65. The current close of $2.59 is 57% above that low.
Does PLX stock pay dividends?
Protalix Biotherapeutics does not currently show a dividend per share in the company data.
What is the Debt / Equity ratio for PLX?
Protalix Biotherapeutics's Debt / Equity ratio is 0.13.